参考文献[1]
LambertE, DasseE, HayeB, et al. TIMPs as multifacial proteins[J]. Crit Rev Oncol Hematol, 2004, 49(3): 187-198. .
[2]
BonnansC, ChouJ, WerbZ. Remodelling the extracellular matrix in development and disease[J]. Nat Rev Mol Cell Biol, 2014, 15(12): 786-801. .
[3]
O′SullivanS, GilmerJF, MedinaC. Matrix metalloproteinases in inflammatory bowel disease：an update[J]. Mediators Inflamm, 2015, 2015(11): 964131. .
[4]
RaviA, GargP, SitaramanSV. Matrix metalloproteinases in inflammatory bowel disease：boon or a bane?[J]. Inflamm Bowel Dis, 2007, 13(1): 97-107. .
[5]
ChircoR, LiuXW, JungKK, et al. Novel functions of TIMPs in cell signaling[J]. Cancer Metastasis Rev, 2006, 25(1): 99-113. .
[6]
di PaolaR, EspositoE, MazzonE, et al. Teupolioside, a phenylpropanoid glycosides of Ajuga reptans, biotechnologically produced by IRBN22 plant cell line, exerts beneficial effects on a rodent model of colitis[J]. Biochem Pharmacol, 2009, 77(5): 845-857. .
[7]
MazzonE, EspositoE, di PaolaR, et al. Effects of verbascoside biotechnologically produced by Syringa vulgaris plant cell cultures in a rodent model of colitis[J]. Naunyn Schmiedebergs Arch Pharmacol, 2009, 380(1): 79-94. .
[8]
MaoJW, HeXM, TangHY, et al. Protective role of metallopro-teinase inhibitor（AE-941）on ulcerative colitis in rats[J]. World J Gastroenterol, 2012, 18(47): 7063-7069. .
[9]
TrivediPP, JenaGB. Role of α-lipoic acid in dextran sulfate sodium-induced ulcerative colitis in mice：studies on inflammation, oxidative stress, DNA damage and fibrosis[J]. Food Chem Toxicol, 2013, 59: 339-355. .
[10]
SchepensM, SchonewilleAJ, VinkC, et al. Supplemental calcium attenuates the colitis-related increase in diarrhea, intestinal permeability, and extracellular matrix breakdown in HLA-B27 transgenic rats[J]. J Nutr, 2009, 139(8): 1525-1533. .
[11]
BertonA, RigotV, HuetE, et al. Involvement of fibronectin type II repeats in the efficient inhibition of gelatinases A and B by long-chain unsaturated fatty acids[J]. J Biol Chem, 2001, 276(23): 20458-20465. .
[12]
GravaghiC, la PerleKM, OgrodwskiP, et al. Cox-2 expression, PGE（2）and cytokines production are inhibited by endogenously synthesized n-3 PUFAs in inflamed colon of fat-1 mice[J]. J Nutr Biochem, 2011, 22(4): 360-365. .
[13]
GramsF, BrandstetterH, D′AloS, et al. Pyrimidine-2, 4, 6-Triones：a new effective and selective class of matrix metallopro-teinase inhibitors[J]. Biol Chem, 2001, 382(8): 1277-1285. .
[14]
O′SullivanS, MedinaC, LedwidgeM, et al. Nitric oxide-matrix metaloproteinase-9 interactions：biological and pharmacological significance--NO and MMP-9 interactions[J]. Biochim Biophys Acta, 2014, 1843(3): 603-617. .
[15]
WangJ, O′SullivanS, HarmonS, et al. Design of barbiturate-nitrate hybrids that inhibit MMP-9 activity and secretion[J]. J Med Chem, 2012, 55(5): 2154-2162. .
[16]
O′SullivanS, WangJ, PigottMT, et al. Inhibition of matrix metalloproteinase-9 by a barbiturate-nitrate hybrid ameliorates dextran sulphate sodium-induced colitis：effect on inflammation-related genes[J]. Br J Pharmacol, 2017, 174(7): 512-524. .
[17]
HuangTY, ChuHC, LinYL, et al. Minocycline attenuates experimental colitis in mice by blocking expression of inducible nitric oxide synthase and matrix metalloproteinases[J]. Toxicol Appl Pharmacol, 2009, 237(1): 69-82.
[18]
HeimesaatMM, DunayIR, FuchsD, et al. Selective gelatinase blockage ameliorates acute DSS colitis[J]. Eur J Microbiol Immunol（Bp）, 2011, 1(3): 228-236. .
[19]
KimYJ, HongKS, ChungJW, et al. Prevention of colitis-associated carcinogenesis with infliximab[J]. Cancer Prev Res （Phila）, 2010, 3(10): 1314-1333. .
[20]
MakitaloL, SipponenT, KarkkainenP, et al. Changes in matrix metalloproteinase（MMP）and tissue inhibitors of metalloproteinases（TIMP）expression profile in Crohn′s disease after immunosuppressive treatment correlate with histological score and calprotectin values[J]. Int J Colorectal Dis, 2009, 24(10): 1157-1167. .
[21]
CastanedaFE, WaliaB, Vijay-KumarM, et al. Targeted deletion of metalloproteinase 9 attenuates experimental colitis in mice：central role of epithelial-derived MMP[J]. Gastroenterology, 2005, 129(6): 1991-2008. .
[22]
Sela-PasswellN, KikkeriR, DymO, et al. Antibodies targeting the catalytic zinc complex of activated matrix metalloproteinases show therapeutic potential[J]. Nat Med, 2011, 18(1): 143-147. .
[23]
MarshallDC, LymanSK, McCauleyS, et al. Selective allosteric inhibition of MMP-9 is efficacious in preclinical models of ulcerative colitis and colorectal cancer[J]. PLoS One, 2015, 10(5): e127063. .
[24]
GargP, Vijay-KumarM, WangL, et al. Matrix metalloproteinase-9-mediated tissue injury overrides the protective effect of matrix metalloproteinase-2 during colitis[J]. Am J Physiol Gastrointest Liver Physiol, 2009, 296(2): G175-G184. .
[25]
CoussensLM, FingletonB, MatrisianLM. Matrix metalloproteinase inhibitors and cancer：trials and tribulations[J]. Science, 2002, 295(5564): 2387-2392. .
[26]
PetersonJT. The importance of estimating the therapeutic index in the development of matrix metalloproteinase inhibitors[J]. Cardiovasc Res, 2006, 69(3): 677-687. .
[27]
GoffinL, FagagniniS, VicariA, et al. Anti-MMP-9 antibody：a promising therapeutic strategy for treatment of inflammatory bowel disease complications with fibrosis[J]. Inflamm Bowel Dis, 2016, 22(9): 2041-2057. .
[28]
SandbornWJ, BhandariBR, FogelR, et al. Randomised clinical trial：a phase 1, dose-ranging study of the anti-matrix metalloproteinase-9 monoclonal antibody GS-5745 versus placebo for ulcerative colitis[J]. Aliment Pharmacol Ther, 2016, 44(2): 157-169. .
[29]
SandbornWJ, BhandariBR, RandallC, et al. Andecaliximab [anti-matrix metalloproteinase-9] induction therapy for ulcerative colitis：a randomised, double-blind, placebo-controlled, phase 2/3 study in patients with moderate to severe disease[J]. J Crohns Colitis, 2018.
[30]
BruynMD, BreynaertC, ArijsI, et al. Inhibition of gelatinase B/MMP-9 does not attenuate colitis in murine models of inflammatory bowel disease[J]. Nature Communications, 2017, 8: 15384. .
